Exploiting Cancer Dependence on Molecular Chaperones: HSP90 Inhibitors Past, Present, and Future

Cancer Drug Design and Discovery: Second Edition

Volumn , Issue , 2013, Pages 239-274

  Sharp, Swee ^a   Jones, Keith ^a   Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Anticancer activity and selectivity; Chemical tools; Client protein degradation; Clinical activity in breast and lung cancer; Molecular chaperone heat shock protein 90 (HSP90); Natural products, geldanamycin, radicicol; Small molecule HSP90 inhibitors; Structure based design

Indexed keywords

EID: 84902071075     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-396521-9.00009-7     Document Type: Chapter

References (199)

1. Al-Lazikani B., Banerji U., Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012, 30:679-692.
2. Yap T.A., Workman P. Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annu Rev Pharmacol Toxicol 2012, 52:549-573.
3. Collins I., Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2006, 2:689-700.
4. Maloney A., Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002, 2:3-24.
5. Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 2004, 206:149-157.
6. Workman P., Burrows F., Neckers L., Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007, 1113:202-216.
7. Neckers L., Workman P. Hsp90 molecular chaperone inhibitors: are we there yet?. Clin Cancer Res 2012, 18:64-76.
8. Travers J., Sharp S., Workman P. HSP90 inhibition: two-pronged exploitation of cancer dependencies. Drug Discov Today 2012, 17:242-252.
9. Csermely P., Schnaider T., Soti C., Prohaszka Z., Nardai G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 1998, 79:129-168.
10. Pearl L.H., Prodromou C., Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008, 410:439-453.
11. Calderwood S.K. Heat shock proteins in breast cancer progression-a suitable case for treatment?. Int J Hyperthermia 2010, 26:681-685.
12. Mayer M.P. Gymnastics of molecular chaperones. Mol Cell 2010, 39:321-331.
13. MacRae T.H. Structure and function of small heat shock/alpha-crystallin proteins: established concepts and emerging ideas. Cell Mol Life Sci 2000, 57:899-913.
14. Wang K., Spector A. ATP causes small heat shock proteins to release denatured protein. Eur J Biochem 2001, 268:6335-6345.
15. Chen B., Piel W.H., Gui L., Bruford E., Monteiro A. The HSP90 family of genes in the human genome: insights into their divergence and evolution. Genomics 2005, 86:627-637.
16. Pearl L.H., Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 2006, 75:271-294.
17. Prodromou C., Roe S.M., O'Brien R., Ladbury J.E., Piper P.W., Pearl L.H. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell. 1997, 90:65-75.
18. Prodromou C., Panaretou B., Chohan S., Siligardi G., O'Brien R., Ladbury J.E., et al. The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains. EMBO J 2000, 19:4383-4392.
19. Panaretou B., Siligardi G., Meyer P., Maloney A., Sullivan J.K., Singh S., et al. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol Cell. 2002, 10:1307-1318.
20. Roe S.M., Ali M.M., Meyer P., Vaughan C.K., Panaretou B., Piper P.W., et al. The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50 (cdc37). Cell. 2004, 116:87-98.
21. Vaughan C.K., Mollapour M., Smith J.R., Truman A., Hu B., Good V.M., et al. Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37. Mol Cell 2008, 31:886-895.
22. Ali M.M., Roe S.M., Vaughan C.K., Meyer P., Panaretou B., Piper P.W., et al. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 2006, 440:1013-1017.
23. Ciocca D.R., Clark G.M., Tandon A.K., Fuqua S.A., Welch W.J., McGuire W.L. Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst 1993, 85:570-574.
24. Kimura E., Enns R.E., Alcaraz J.E., Arboleda J., Slamon D.J., Howell S.B. Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60. J Clin Oncol 1993, 11:891-898.
25. Ralhan R., Kaur J. Differential expression of Mr 70,000 heat shock protein in normal, premalignant, and malignant human uterine cervix. Clin Cancer Res 1995, 1:1217-1222.
26. Santarosa M., Favaro D., Quaia M., Galligioni E. Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients. Eur J Cancer 1997, 33:873-877.
27. Yufu Y., Nishimura J., Nawata H. High constitutive expression of heat shock protein 90 alpha in human acute leukemia cells. Leuk Res 1992, 16:597-605.
28. Chant I.D., Rose P.E., Morris A.G. Analysis of heat-shock protein expression in myeloid leukaemia cells by flow cytometry. Br J Haematol 1995, 90:163-168.
29. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Fanourakis G., Gu X., et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002, 99:14374-14379.
30. McCarthy M.M., Pick E., Kluger Y., Gould-Rothberg B., Lazova R., Camp R.L., et al. HSP90 as a marker of progression in melanoma. Ann Oncol 2008, 19:590-594.
31. Pick E., Kluger Y., Giltnane J.M., Moeder C., Camp R.L., Rimm D.L., et al. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 2007, 67:2932-2937.
32. Gallegos Ruiz M.I., Floor K., Roepman P., Rodriguez J.A., Meijer G.A., Mooi W.J., et al. Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One 2008, 3. e0001722.
33. Li C.F., Huang W.W., Wu J.M., Yu S.C., Hu T.H., Uen Y.H., et al. Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors. Clin Cancer Res 2008, 14:7822-7831.
34. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5:761-772.
35. Whitesell L., Bagatell R., Falsey R. The stress response: implications for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets 2003, 3:349-358.
36. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
37. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008, 118:3065-3074.
38. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
39. Pratilas C.A., Taylor B.S., Ye Q., Viale A., Sander C., Solit D.B., et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 2009, 106:4519-4524.
40. Hostein I., Robertson D., DiStefano F., Workman P., Clarke P.A. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001, 61:4003-4009.
41. Chiosis G., Neckers L. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem Biol 2006, 1:279-284.
42. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425:407-410.
43. da Rocha Dias S., Friedlos F., Light Y., Springer C., Workman P., Marais R. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2005, 65:10686-10691.
44. Grbovic O.M., Basso A.D., Sawai A., Ye Q., Friedlander P., Solit D., et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci U S A 2006, 103:57-62.
45. Weinstein I.B., Joe A.K. Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006, 3:448-457.
46. Taipale M., Krykbaeva I., Koeva M., Kayatekin C., Westover K.D., Karras G.I., et al. Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell 2012, 150:987-1001.
47. Samant R.S., Workman P. Molecular biology: choose your protein partners. Nature 2012, 490:351-352.
48. Whitesell L., Mimnaugh E.G., De Costa B., Myers C.E., Neckers L.M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 1994, 91:8324-8328.
49. Roe S.M., Prodromou C., O'Brien R., Ladbury J.E., Piper P.W., Pearl L.H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999, 42:260-266.
50. Workman P., Collins I. Probing the probes: fitness factors for small molecule tools. Chem Biol 2010, 17:561-577.
51. Chene P. ATPases as drug targets: learning from their structure. Nat Rev Drug Discov 2002, 1:665-673.
52. Grenert J.P., Sullivan W.P., Fadden P., Haystead T.A., Clark J., Mimnaugh E., et al. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 1997, 272:23843-23850.
53. Xu W., Marcu M., Yuan X., Mimnaugh E., Patterson C., Neckers L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci U S A 2002, 99:12847-12852.
54. Schnur R.C., Corman M.L., Gallaschun R.J., Cooper B.A., Dee M.F., Doty J.L., et al. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 1995, 38:3806-3812.
55. Porter J.R., Ge J., Lee J., Normant E., West K. Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy. Curr Top Med Chem 2009, 9:1386-1418.
56. Supko J.G., Hickman R.L., Grever M.R., Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995, 36:305-315.
57. Solit D.B., Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov Today 2008, 13:38-43.
58. Munster P.N., Basso A., Solit D., Norton L., Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin. Cancer Res 2001, 7:2155-2158.
59. Banerji U., O'Donnell A., Scurr M., Pacey S., Stapleton S., Asad Y., et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005, 23:4152-4161.
60. Banerji U., Walton M., Raynaud F., Grimshaw R., Kelland L., Valenti M., et al. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 2005, 11:7023-7032.
61. Workman P. How much gets there and what does it do? The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 2003, 9:891-902.
62. Yap T.A., Sandhu S.K., Workman P., de Bono J.S. Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010, 10:514-523.
63. Pacey S., Gore M., Chao D., Banerji U., Larkin J., Sarker S., et al. A phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs 2012, 30:341-349.
64. Banerji U., Affolter A., Judson I., Marais R., Workman P. BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther 2008, 7:737-739.
65. Modi S., Stopeck A., Linden H., Solit D., Chandarlapaty S., Rosen N., et al. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011, 17:5132-5139.
66. Rodrigues L.M., Chung Y.L., Al Saffar N.M., Sharp S.Y., Jackson L.E., Banerji U., et al. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by magnetic resonance spectroscopy. BMC Res Notes 2012, 5:250.
67. Munster P.N., Marchion D.C., Basso A.D., Rosen N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. Cancer Res 2002, 62:3132-3137.
68. Richardson P.G., Chanan-Khan A.A., Lonial S., Krishnan A.Y., Carroll M.P., Alsina M., et al. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br J Haematol 2011, 153:729-740.
69. Richardson P.G., Mitsiades C.S., Laubach J.P., Lonial S., Chanan-Khan A.A., Anderson K.C. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol 2011, 152:367-379.
70. Tse A.N., Sheikh T.N., Alan H., Chou T.C., Schwartz G.K. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1. Mol Pharmacol 2009, 75:124-133.
71. Arlander S.J., Felts S.J., Wagner J.M., Stensgard B., Toft D.O., Karnitz L.M. Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones. J Biol Chem 2006, 281:2989-2998.
72. Hubbard J., Erlichman C., Toft D.O., Qin R., Stensgard B.A., Felten S., et al. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. Invest New Drugs 2011, 29:473-480.
73. Reikvam H., Ersvaer E., Bruserud O. Heat shock protein 90-a potential target in the treatment of human acute myelogenous leukemia. Curr Cancer Drug Targets 2009, 9:761-776.
74. Weisberg E., Barrett R., Liu Q., Stone R., Gray N., Griffin J.D. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat 2009, 12:81-89.
75. Peng C., Brain J., Hu Y., Goodrich A., Kong L., Grayzel D., et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 2007, 110:678-685.
76. O'Hare T., Eide C.A., Deininger M.W. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opin Investig Drugs 2008, 17:865-878.
77. Castro J.E., Prada C.E., Loria O., Kamal A., Chen L., Burrows F.J., et al. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood 2005, 106:2506-2512.
78. Arteaga C.L. Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?. Clin Cancer Res 2011, 17:4919-4921.
79. Smith V., Sausville E.A., Camalier R.F., Fiebig H.H., Burger A.M. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 2005, 56:126-137.
80. Egorin M.J., Lagattuta T.F., Hamburger D.R., Covey J.M., White K.D., Musser S.M., et al. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 2002, 49:7-19.
81. Kaur G., Belotti D., Burger A.M., Fisher-Nielson K., Borsotti P., Riccardi E., et al. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 2004, 10:4813-4821.
82. Pacey S., Wilson R.H., Walton M., Eatock M.M., Hardcastle A., Zetterlund A., et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 2011, 17:1561-1570.
83. Solit D.B., Ivy S.P., Kopil C., Sikorski R., Morris M.J., Slovin S.F., et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007, 13:1775-1782.
84. Solit D.B., Zheng F.F., Drobnjak M., Munster P.N., Higgins B., Verbel D., et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002, 8:986-993.
85. Jhaveri K., Miller K., Rosen L., Schneider B., Chap L., Hannah A., et al. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors. Clin Cancer Res 2012, 18:5090-5098.
86. Ronnen E.A., Kondagunta G.V., Ishill N., Sweeney S.M., Deluca J.K., Schwartz L., et al. A phase II trial of 17-(allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 2006, 24:543-546.
87. Solit D.B., Osman I., Polsky D., Panageas K.S., Daud A., Goydos J.S., et al. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 2008, 14:8302-8307.
88. Erlichman C. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs 2009, 18:861-868.
89. Ge J., Normant E., Porter J.R., Ali J.A., Dembski M.S., Gao Y., et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem 2006, 49:4606-4615.
90. Taldone T., Gozman A., Maharaj R., Chiosis G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 2008, 8:370-374.
91. Egorin M.J., Zuhowski E.G., Rosen D.M., Sentz D.L., Covey J.M., Eiseman J.L. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol 2001, 47:291-302.
92. Kelland L.R., Sharp S.Y., Rogers P.M., Myers T.G., Workman P. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999, 91:1940-1949.
93. Pacey S., Banerji U., Judson I., Workman P. Hsp90 inhibitors in the clinic. Handb Exp Pharmacol 2006, 331-358.
94. Guo W., Reigan P., Siegel D., Zirrolli J., Gustafson D., Ross D. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 2005, 65:10006-10015.
95. Siegel D., Yan C., Ross D. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol 2012, 83:1033-1040.
96. Gaspar N., Sharp S.Y., Pacey S., Jones C., Walton M., Vassal G., et al. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res 2009, 69:1966-1975.
97. Sydor J.R., Normant E., Pien C.S., Porter J.R., Ge J., Grenier L., et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A 2006, 103:17408-17413.
98. Sequist L.V., Gettinger S., Senzer N.N., Martins R.G., Janne P.A., Lilenbaum R., et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010, 28:4953-4960.
99. Janin Y.L. ATPase inhibitors of heat-shock protein 90, second season. Drug Discov Today 2010, 15:342-353.
100. Oh W.K., Galsky M.D., Stadler W.M., Srinivas S., Chu F., Bubley G., et al. Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology 2011, 78:626-630.
101. Kwon H.J., Yoshida M., Fukui Y., Horinouchi S., Beppu T. Potent and specific inhibition of p60v-src protein kinase both in vivo and in vitro by radicicol. Cancer Res 1992, 52:6926-6930.
102. Zhao J.F., Nakano H., Sharma S. Suppression of RAS and MOS transformation by radicicol. Oncogene 1995, 11:161-173.
103. Schulte T.W., Akinaga S., Soga S., Sullivan W., Stensgard B., Toft D., et al. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones 1998, 3:100-108.
104. Soga S., Neckers L.M., Schulte T.W., Shiotsu Y., Akasaka K., Narumi H., et al. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res 1999, 59:2931-2938.
105. Agatsuma T., Ogawa H., Akasaka K., Asai A., Yamashita Y., Mizukami T., et al. Halohydrin and oxime derivatives of radicicol: synthesis and antitumor activities. Bioorg Med Chem 2002, 10:3445-3454.
106. Janin Y.L. Heat shock protein 90 inhibitors. A text book example of medicinal chemistry?. J Med Chem 2005, 48:7503-7512.
107. Hellwig V., Mayer-Bartschmid A., Muller H., Greif G., Kleymann G., Zitzmann W., et al. Pochonins A-F, new antiviral and antiparasitic resorcylic acid lactones from Pochonia chlamydosporia var. catenulata. J Nat Prod 2003, 66:829-837.
108. Proisy N., Sharp S.Y., Boxall K., Connelly S., Roe S.M., Prodromou C., et al. Inhibition of Hsp90 with synthetic macrolactones: synthesis and structural and biological evaluation of ring and conformational analogs of radicicol. Chem Biol 2006, 13:1203-1215.
109. Day J.E., Sharp S.Y., Rowlands M.G., Aherne W., Hayes A., Raynaud F.I., et al. Targeting the Hsp90 molecular chaperone with novel macrolactams. Synthesis, structural, binding, and cellular studies. ACS Chem Biol 2011, 6:1339-1347.
110. Cheung K.M., Matthews T.P., James K., Rowlands M.G., Boxall K.J., Sharp S.Y., et al. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg Med Chem Lett 2005, 15:3338-3343.
111. Sharp S.Y., Boxall K., Rowlands M., Prodromou C., Roe S.M., Maloney A., et al. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res 2007, 67:2206-2216.
112. Sharp S.Y., Prodromou C., Boxall K., Powers M.V., Holmes J.L., Box G., et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther 2007, 6:1198-1211.
113. Eccles S.A., Massey A., Raynaud F.I., Sharp S.Y., Box G., Valenti M., et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008, 68:2850-2860.
114. Brough P.A., Aherne W., Barril X., Borgognoni J., Boxall K., Cansfield J.E., et al. 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 2008, 51:196-218.
115. Sessa C., Shapiro G.I., Bhalla K.N., Britten C., Jacks K.S., Mita M., et al. First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Can Res 2013.
116. Wainberg Z.A., Anghel A., Rogers A.M., Desai A.J., Kalous O., Conklin D., et al. Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer. Mol Cancer Ther 2013, 12:509-519.
117. Jensen M.R., Schoepfer J., Radimerski T., Massey A., Guy C.T., Brueggen J., et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 2008, 10:R33.
118. Kong A, Rea D, Ahmed S, Beck JT, López López R, Biganzoli L, et-al. Phase Ib/II study of the HSP90 inhibitor AUY922, in combination with trastuzumab, in patients with HER2+ advanced breast cancer. 2012. ASCO. Abstract No: 530.
119. Garon EB, Moran T, Barlesi F, Gandhi L, Sequist LV, Kim S-W, et al. Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC). 2012. ASCO. Abstract No: 7543.
120. Ying W., Du Z., Sun L., Foley K.P., Proia D.A., Blackman R.K., et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 2012, 11:475-484.
121. Shimamura T., Perera S.A., Foley K.P., Sang J., Rodig S.J., Inoue T., et al. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res 2012, 18:4973-4985.
122. Acquaviva J., Smith D.L., Sang J., Friedland J.C., He S., Sequeira M., et al. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther 2012, 11:2633-2643.
123. Goldman J.W., Raju R.N., Gordon G.A., El-Hariry I., Teofilivici F., Vukovic V.M., et al. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer 2013, 13:152.
124. Choi H.K., Lee K. Recent updates on the development of ganetespib as a Hsp90 inhibitor. Arch Pharm Res 2012, 35:1855-1859.
125. Sang J., Acquaviva J., Friedland J.C., Smith D.L., Sequeira M., Zhang C., et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov 2013, 3:430-443.
126. Socinski M.A., Goldman J., El-Hariry I., Koczywas M., Vukovic V., Horn L., et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically-defined advanced non-small cell lung cancer. Clin Cancer Res 2013.
127. Ramalingam SS, Zaric B, Goss GD, Manegold C Sr., Rosell R, Vukovic V, et-al. Preliminary results from a randomized 2b/3 study of ganetespib and docetaxel combination versus docetaxel in advanced NSCLC (the GALAXY Trial, NCT01348126). 2012. ESMO. Abstract #1248P_PR.
128. Woodhead A.J., Angove H., Carr M.G., Chessari G., Congreve M., Coyle J.E., et al. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-di hydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem 2010, 53:5956-5969.
129. Graham B., Curry J., Smyth T., Fazal L., Feltell R., Harada I., et al. The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer. Cancer Sci 2012, 103:522-527.
130. Smyth T., Van Looy T., Curry J.E., Rodriguez-Lopez A.M., Wozniak A., Zhu M., et al. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models. Mol Cancer Ther 2012, 11:1799-1808.
131. Nakashima T., Ishii T., Tagaya H., Seike T., Nakagawa H., Kanda Y., et al. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clin Cancer Res 2010, 16:2792-2802.
132. Sharp S.Y., Roe S.M., Kazlauskas E., Cikotiene I., Workman P., Matulis D., et al. Co-crystallization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1,2,3-thiadiazole hsp90 inhibitors. PLoS One 2012, 7:e44642.
133. Prodromou C., Nuttall J.M., Millson S.H., Roe S.M., Sim T.S., Tan D., et al. Structural basis of the radicicol resistance displayed by a fungal hsp90. ACS Chem Biol 2009, 4:289-297.
134. Piper P.W., Millson S.H. Spotlight on the microbes that produce heat shock protein 90-targeting antibiotics. Open Biol 2012, 2:120138.
135. Chiosis G. Discovery and development of purine-scaffold Hsp90 inhibitors. Curr Top Med Chem 2006, 6:1183-1191.
136. Chiosis G., Timaul M.N., Lucas B., Munster P.N., Zheng F.F., Sepp-Lorenzino L., et al. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol 2001, 8:289-299.
137. Wright L., Barril X., Dymock B., Sheridan L., Surgenor A., Beswick M., et al. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem Biol 2004, 11:775-785.
138. Biamonte M.A., Shi J., Hong K., Hurst D.C., Zhang L., Fan J., et al. Orally active purine-based inhibitors of the heat shock protein 90. J Med Chem 2006, 49:817-828.
139. He H., Zatorska D., Kim J., Aguirre J., Llauger L., She Y., et al. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J Med Chem 2006, 49:381-390.
140. Zhang L., Fan J., Vu K., Hong K., Le Brazidec J.Y., Shi J., et al. 7'-substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors. J Med Chem 2006, 49:5352-5362.
141. Rodina A., Vilenchik M., Moulick K., Aguirre J., Kim J., Chiang A., et al. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nat Chem Biol 2007, 3:498-507.
142. Dickson M.A., Okuno S.H., Keohan M.L., Maki R.G., D'Adamo D.R., Akhurst T.J., et al. Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann Oncol 2013, 24:252-257.
143. Shi J., Van de Water R., Hong K., Lamer R.B., Weichert K.W., Sandoval C.M., et al. EC144 is a potent inhibitor of the heat shock protein 90. J Med Chem 2012, 55:7786-7795.
144. Bao R., Lai C.J., Qu H., Wang D., Yin L., Zifcak B., et al. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res 2009, 15:4046-4057.
145. Kim S.H., Bajji A., Tangallapally R., Markovitz B., Trovato R., Shenderovich M., et al. Discovery of (2S)-1-[4-(2-{6-amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9H-purin-9-yl}et hyl)piperidin-1-yl]-2-hydroxypropan-1-one (MPC-3100), a purine-based Hsp90 inhibitor. J Med Chem 2012, 55:7480-7501.
146. Brough P.A., Barril X., Borgognoni J., Chene P., Davies N.G., Davis B., et al. Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. J Med Chem 2009, 52:4794-4809.
147. Fadden P., Huang K.H., Veal J.M., Steed P.M., Barabasz A.F., Foley B., et al. Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. Chem Biol 2010, 17:686-694.
148. Chandarlapaty S., Sawai A., Ye Q., Scott A., Silinski M., Huang K., et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 2008, 14:240-248.
149. Rajan A., Kelly R.J., Trepel J.B., Kim Y.S., Alarcon S.V., Kummar S., et al. A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res 2011, 17:6831-6839.
150. Zapf C.W., Bloom J.D., McBean J.L., Dushin R.G., Nittoli T., Ingalls C., et al. Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity. Bioorg Med Chem Lett 2011, 21:2278-2282.
151. Zapf C.W., Bloom J.D., McBean J.L., Dushin R.G., Nittoli T., Otteng M., et al. Macrocyclic lactams as potent Hsp90 inhibitors with excellent tumor exposure and extended biomarker activity. Bioorg Med Chem Lett 2011, 21:3411-3416.
152. Zapf C.W., Bloom J.D., McBean J.L., Dushin R.G., Golas J.M., Liu H., et al. Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model. Bioorg Med Chem Lett 2011, 21:3627-3631.
153. Zapf C.W., Bloom J.D., Li Z., Dushin R.G., Nittoli T., Otteng M., et al. Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model. Bioorg Med Chem Lett 2011, 21:4602-4607.
154. Suda A., Koyano H., Hayase T., Hada K., Kawasaki K., Komiyama S., et al. Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors. Bioorg Med Chem Lett 2012, 22:1136-1141.
155. Bussenius J., Blazey C.M., Aay N., Anand N.K., Arcalas A., Baik T., et al. Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90. Bioorg Med Chem Lett 2012, 22:5396-5404.
156. Paraiso K.H., Haarberg H.E., Wood E., Rebecca V.W., Chen Y.A., Xiang Y., et al. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 2012, 18:2502-2514.
157. Menezes D.L., Taverna P., Jensen M.R., Abrams T., Stuart D., Yu G.K., et al. The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo. Mol Cancer Ther 2012, 11:730-739.
158. Khong T., Spencer A. Targeting HSP90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. Mol Cancer Ther 2011, 10:1909-1917.
159. Buchstaller H.P., Eggenweiler H.M., Sirrenberg C., Gradler U., Musil D., Hoppe E., et al. Fragment-based discovery of hydroxy-indazole-carboxamides as novel small molecule inhibitors of Hsp90. Bioorg Med Chem Lett 2012, 22:4396-4403.
160. Zehnder L., Bennett M., Meng J., Huang B., Ninkovic S., Wang F., et al. Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide. J Med Chem 2011, 54:3368-3385.
161. Vallee F., Carrez C., Pilorge F., Dupuy A., Parent A., Bertin L., et al. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone. J Med Chem 2011, 54:7206-7219.
162. Davies N.G., Browne H., Davis B., Drysdale M.J., Foloppe N., Geoffrey S., et al. Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization. Bioorg Med Chem 2012, 20:6770-6789.
163. Yun B.G., Huang W., Leach N., Hartson S.D., Matts R.L. Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions. Biochemistry 2004, 43:8217-8229.
164. Donnelly A., Blagg B.S. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem 2008, 15:2702-2717.
165. Allan R.K., Mok D., Ward B.K., Ratajczak T. Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization. J Biol Chem 2006, 281:7161-7171.
166. Marcu M.G., Neckers L.M. The C-terminal half of heat shock protein 90 represents a second site for pharmacologic intervention in chaperone function. Curr Cancer Drug Targets 2003, 3:343-347.
167. Shelton S.N., Shawgo M.E., Matthews S.B., Lu Y., Donnelly A.C., Szabla K., et al. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol Pharmacol 2009, 76:1314-1322.
168. Samadi A.K., Zhang X., Mukerji R., Donnelly A.C., Blagg B.S., Cohen M.S. A novel C-terminal HSP90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells. Cancer Lett 2011, 312:158-167.
169. Matts R.L., Dixit A., Peterson L.B., Sun L., Voruganti S., Kalyanaraman P., et al. Elucidation of the Hsp90 C-terminal inhibitor binding site. ACS Chem Biol 2011, 6:800-807.
170. Zhao H., Donnelly A.C., Kusuma B.R., Brandt G.E., Brown D., Rajewski R.A., et al. Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents. J Med Chem 2011, 54:3839-3853.
171. Kusuma B.R., Zhang L., Sundstrom T., Peterson L.B., Dobrowsky R.T., Blagg B.S. Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity. J Med Chem 2012, 55:5797-5812.
172. Powers M.V., Jones K., Barillari C., Westwood I., van Montfort R.L., Workman P. Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone?. Cell Cycle 2010, 9:1542-1550.
173. Kunicki J.B., Petersen M.N., Alexander L.D., Ardi V.C., McConnell J.R., McAlpine S.R. Synthesis and evaluation of biotinylated sansalvamide A analogs and their modulation of Hsp90. Bioorg Med Chem Lett 2011, 21:4716-4719.
174. Vasko R.C., Rodriguez R.A., Cunningham C.N., Ardi V.C., Agard D.A., McAlpine S.R. Mechanistic studies of Sansalvamide A-amide: an allosteric modulator of Hsp90. ACS Med Chem Lett 2010, 1:4-8.
175. Davenport J., Manjarrez J.R., Peterson L., Krumm B., Blagg B.S., Matts R.L. Gambogic acid, a natural product inhibitor of Hsp90. J Nat Prod 2011, 74:1085-1092.
176. Powers M.V., Workman P. Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett 2007, 581:3758-3769.
177. Bagatell R., Paine-Murrieta G.D., Taylor C.W., Pulcini E.J., Akinaga S., Benjamin I.J., et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 2000, 6:3312-3318.
178. Powers M.V., Clarke P.A., Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008, 14:250-262.
179. Evans C.G., Chang L., Gestwicki J.E. Heat shock protein 70 (hsp70) as an emerging drug target. J Med Chem 2010, 53:4585-4602.
180. Hadchity E., Aloy M.T., Paulin C., Armandy E., Watkin E., Rousson R., et al. Heat shock protein 27 as a new therapeutic target for radiation sensitization of head and neck squamous cell carcinoma. Mol Ther 2009, 17:1387-1394.
181. Davenport E.L., Zeisig A., Aronson L.I., Moore H.E., Hockley S., Gonzalez D., et al. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia 2010, 24:1804-1807.
182. McDowell C.L., Bryan Sutton R., Obermann W.M. Expression of Hsp90 chaperone [corrected] proteins in human tumor tissue. Int J Biol Macromol 2009, 45:310-314.
183. Smith J.R., Clarke P.A., de Billy E., Workman P. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene 2009, 28:157-169.
184. Holmes J.L., Sharp S.Y., Hobbs S., Workman P. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2008, 68:1188-1197.
185. Forafonov F., Toogun O.A., Grad I., Suslova E., Freeman B.C., Picard D. p23/Sba1p protects against Hsp90 inhibitors independently of its intrinsic chaperone activity. Mol Cell Biol 2008, 28:3446-3456.
186. Vaughan C.K., Gohlke U., Sobott F., Good V.M., Ali M.M., Prodromou C., et al. Structure of an Hsp90-Cdc37-Cdk4 complex. Mol Cell 2006, 23:697-707.
187. Plescia J., Salz W., Xia F., Pennati M., Zaffaroni N., Daidone M.G., et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005, 7:457-468.
188. Mollapour M., Tsutsumi S., Donnelly A.C., Beebe K., Tokita M.J., Lee M.J., et al. Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol Cell 2010, 37:333-343.
189. Mollapour M., Neckers L. Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochim Biophys Acta 2012, 1823:648-655.
190. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005, 280:26729-26734.
191. de Bono J.S., Kristeleit R., Tolcher A., Fong P., Pacey S., Karavasilis V., et al. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res 2008, 14:6663-6673.
192. Torres E.M., Dephoure N., Panneerselvam A., Tucker C.M., Whittaker C.A., Gygi S.P., et al. Identification of aneuploidy-tolerating mutations. Cell 2010, 143:71-83.
193. Tang Y.C., Williams B.R., Siegel J.J., Amon A. Identification of aneuploidy-selective antiproliferation compounds. Cell 2011, 144:499-512.
194. Duerfeldt A.S., Peterson L.B., Maynard J.C., Ng C.L., Eletto D., Ostrovsky O., et al. Development of a Grp94 inhibitor. J Am Chem Soc 2012, 134:9796-9804.
195. Patel M.N., Halling-Brown M.D., Tym J.E., Workman P., Al-Lazikani B. Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov 2013, 12:35-50.
196. Dai C., Whitesell L., Rogers A.B., Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007, 130:1005-1018.
197. Moulick K., Ahn J.H., Zong H., Rodina A., Cerchietti L., Dagama G., et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol 2011, 7:818-826.
198. Darby J.F., Workman P. Chemical biology: many faces of a cancer-supporting protein. Nature 2011, 478:334-335.
199. Polier S., Samant R.S., Clarke P.A., Workman P., Prodromou C., Pearl L.H. ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Nat Chem Biol 2013, 9:307-312.